Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial

Author:

Zheng Xubin1,Gui Xuwei1,Yao Lan1,Ma Jun1,He Yifan1,Lou Hai1,Gu Jin1,Ying Ruoyan1,Chen Liping1,Sun Qin1,Liu Yidian1,Ho Chih-Ming23,Lee Bai-Yu4,Clemens Daniel L.4,Horwitz Marcus A.4,Ding Xianting5,Hao Xiaohui1,Yang Hua1,Sha Wei1

Affiliation:

1. Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of China

2. Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, USA

3. Department of Bioengineering, University of California, Los Angeles, CA, USA

4. Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USA

5. Institute for Personalized Medicine, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

Funder

Clinical Research Plan of SHDC

Bill and Melinda Gates Foundation

Global Health

Shanghai Clinical Research Center for Infectious Disease

Shanghai Medical Leading Talents Training Program

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Reference29 articles.

1. WHO. Global tuberculosis report 2021 Geneva: World Health Organization. [cited 2021]. Available from: https://www.who.int/publications/i/item/9789240037021; 2021

2. The Global Landscape of Tuberculosis Therapeutics

3. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

4. WHO. WHO consolidated guidelines on tuberculosis Module 4: treatment - drug-susceptible tuberculosis treatment Geneva2022 [updated 2022 May]. Available from: https://www.who.int/publications/i/item/9789240048126

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3